AI modeling transforms drug development from a numbers game of screening millions of compounds to an engineering discipline. Researchers can model molecular systems upfront, understand key parameters, and design solutions for a specific problem, turning a costly screening process into a rapid, targeted design cycle.

To evolve AI from pattern matching to understanding physics for protein engineering, structural data is insufficient. Models need physical parameters like Gibbs free energy (delta-G), obtainable from affinity measurements, to become truly predictive and transformative for therapeutic development.

The transition to an engineering discipline in drug discovery, analogous to aeronautics, means using powerful in silico models to get much closer to a final product before physical testing. This reduces reliance on iterative, expensive, and time-consuming wet lab experiments.

Unlike traditional methods that simulate physical interactions like a key in a lock, ProPhet's AI learns the fundamental patterns governing why certain molecules and proteins interact. This allows for prediction without needing slow, expensive, and often impossible physical or computational simulations.

Unlike antibodies with flexible loops allowing for induced fit, de novo designed proteins are hyper-rigid. This pre-organized structure leads to rapid binding (fast on-rates) but also makes them susceptible to rapid unbinding (fast off-rates), as the rigid interface is more easily displaced by solvent.

Moving beyond traditional models focused on structural fit, Expedition's platform incorporates quantum chemistry. It uses Density Functional Theory (DFT) to model electron density and predict the actual probability of a covalent bond forming, enabling the design of specific molecules for previously "undruggable" targets.

AlphaFold 2 was a breakthrough for predicting single protein structures. However, this success highlighted the much larger, unsolved challenges of modeling protein interactions, their dynamic movements, and the actual folding process, which are critical for understanding disease and drug discovery.

Beyond accelerating timelines, AI's real value lies in its ability to design molecules for targets previously considered 'hard-to-drug.' These models operate on different principles than traditional lab methods and are indifferent to historical challenges, opening up entirely new therapeutic possibilities.

The immediate goal for AI in drug design is finding initial "hits" for difficult targets. The true endgame, however, is to train models on manufacturability data—like solubility and stability—so they can generate molecules that are already optimized, drastically compressing the development timeline.